Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Internalizing Anti-CD74 Antibodies and Methods of Use

a technology of human anticd74 and anti-cd74, which is applied in the field of humanized, chimeric and human anticd74 antibodies or fragments thereof or antibody fusion proteins, can solve the problems of limited clinical use of mll1, just as with most other promising murine antibodies, and the limitation of full-length anti-cd74 mab to limit the diagnostic and therapeutic usefulness of such antibodies and antibody conjugates

Inactive Publication Date: 2011-10-06
IMMUNOMEDICS INC
View PDF17 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Increasing the concentration of the radiolabel to increase the dosage to the tumor is counterproductive, generally, as this also increases exposure of healthy tissue to radioactivity.
The clinical use of mLL1, just as with most other promising murine antibodies, has been limited by the development in humans of a human anti-mouse antibody (HAMA) response.
This use of the full-length anti-CD74 mAb can limit the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Internalizing Anti-CD74 Antibodies and Methods of Use
  • Internalizing Anti-CD74 Antibodies and Methods of Use
  • Internalizing Anti-CD74 Antibodies and Methods of Use

Examples

Experimental program
Comparison scheme
Effect test

example 1

Molecular Cloning and Sequence Elucidation for LL1 Heavy and Light Chain Variable Regions

[0163]The V gene of mLL1 was obtained by RT-PCR using VK5′-4 and VK1FOR primers as described by Leung et al. 1993 and Orlandi et al. (PNAS 86:3833-3837. (1989), respectively, and cloned into pCR2.1 AT-cloning vector (Invitrogen). Multiple clones were sequenced to eliminate possible errors resulted from PCR reaction. Majority of clones (6) contained an identical murine V sequence, which was designated as LL1V and the sequence is shown in FIG. 1B. Comparison with other mouse Vk sequences revealed LL1Vk is a member of the kappa light chain subclass II.

[0164]Since RT-PCR failed to yield a full-length sequence encoding a mouse VH gene, the second cloning approach, rapid amplification of cDNA 5′-ends (5′-RACE) was employed. The adaptor-ligated cDNA prepared from LL1 hybridoma cells was amplified by PCR using a universal anchor primer (Life Technologies) and a gene specific primer, CH-1B (Leung et al. ...

example 2

Construction of the Expression Vector for Chimeric LL1

[0165]To evaluated the authenticity of the cloned Fv for LL1, a chimeric LL1 (cLL1) was constructed and expressed. The nucleotide residues 7-12 of LL1Vk were modified to a PvuII restriction site, CAGCTG, by PCR with primers LL1VK-PvuII and VK1 FOR. The resulting PCR product was digested with PvuII and BglII (partially, due to the presence of an internal BglII site in the Vk) and force-cloned into a pBR327-based staging vector (digested with PvuII and BclI) VKpBR2, which contained same Ig promoter, signal peptide sequence and convenient restriction sites to facilitate in-frame ligation of the VK PCR product as used by Orlandi et al., 1989 and Leung et al., 1994.

LL1VK-PvuII(SEQ ID NO: 23)5′GAT GTT CAG CTG ACC CAA ACT CCA CTC TCC-3′

[0166]Similarly, the nucleotide sequences at positions 10-15 and 345-351 of LL1VH were converted to PstI and BstEII, respectively, by PCR with primers LL1 B-1 and LL1F-1. The VH PCR product was then diges...

example 3

Transfection and Expression of cLL1

[0169]Approximately 30 μg of cLL1pdHL2 was linerized by digestion with SaIl and transfected into Sp2 / 0-Ag14 cells by electroporation. The transfected cells were plated into 96-well plate for 2 days and then selected for MTX resistance. Supernatants from colonies surviving selection were monitored for chimeric antibody secretion by ELISA assay. Positive cell clones were expanded and cLL1 was purified from cell culture supernatant by affinity chromatograpgy on a Protein A column.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Forceaaaaaaaaaa
Login to View More

Abstract

The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

Description

[0001]This application is a divisional of U.S. Ser. No. 13 / 047,515, filed Mar. 14, 2011, which is a divisional of U.S. Ser. No. 12 / 794,823 (now issued U.S. Pat. No. 7,931,903), filed Jun. 7, 2010, which is a divisional of U.S. Ser. No. 11 / 867,775 (now issued U.S. Pat. No. 7,772,373), filed Oct. 5, 2007, which is a continuation of U.S. Ser. No. 10 / 377,122 (now issued U.S. Pat. No. 7,312,318), filed Mar. 3, 2003, which claimed the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60 / 360,259, filed Mar. 1, 2002, each of which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION [0002]1. Field of the Invention[0003]The present invention relates to humanized, chimeric and human anti-CD74 antibodies or fragments thereof or antibody fusion proteins comprising at least one anti-CD74 antibody, particularly monoclonal antibodies (mAbs), therapeutic and diagnostic conjugates of humanized, chimeric and human anti-CD74 mAbs or fragments thereof, and m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/46C07K16/28C12N9/96C07K19/00A61P35/02
CPCA61K45/06A61K47/48561A61K51/1027A61K2039/505A61K38/00C07K16/2896C07K2317/24C07K2317/77C07K16/2833A61K47/6849A61P17/00A61P21/00A61P25/14A61P31/00A61P35/00A61P35/02A61P37/00A61P37/02A61P37/06A61P3/10C07K16/28G01N33/574A61K39/395
Inventor HANSEN, HANS J.QU, ZHENGXINGGOLDENBERG, DAVID M.
Owner IMMUNOMEDICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com